Related content

Ameliorating effect of the novel dipeptidyl peptidase‐4 inhibitor teneligliptin on psoriasis: A report of two cases

By  

THE JOURNAL OF DERMATOLOGY, Vol. 42, Iss. 11, 2015-11 ,pp. : 1094-1097

John Wiley & Sons Inc

Access to resources Recommend Favorite

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes

By Hanefeld Markolf   Herman Gary A.   Wu Mei   Mickel Carolyn   Sanchez Matilde   Stein Peter P.    

Current Medical Research and Opinion, Vol. 23, Iss. 6, 2007-06 ,pp. : 1329-1339

Informa Healthcare

Access to resources Recommend Favorite

How attractive is the combination of a sodium glucose co‐transporter 2 inhibitor with a dipeptidyl peptidase 4 inhibitor in the treatment of type 2 diabetes?

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 613-615

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety of Dipeptidyl Peptidase 4 Inhibitors for Treatment of Type 2 Diabetes

By  

Current Drug Safety, Vol. 6, Iss. 5, 2011-11 ,pp. : 304-309

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacological characterization of ZYDPLA1, a novel long‐acting dipeptidyl peptidase‐4 inhibitor 一种新型的长效二肽基肽酶‐4抑制剂ZYDPLA1的药理特性

By  

JOURNAL OF DIABETES, Vol. 7, Iss. 5, 2015-09 ,pp. : 708-717

John Wiley & Sons Inc

Access to resources Recommend Favorite